AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England

LONDON: AstraZeneca and Daiichi ‌Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England’s state-run health care system, expanding access to a drug that has been available in Scotland since 2023. The companies said they will now seek approval for access from health bodies in Wales and Northern Ireland. The approval by the National...